ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 130 filers reported holding ACHILLION PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is 1.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $397,000 | +21.8% | 65,813 | -27.3% | 0.06% | -1.5% |
| Q3 2019 | $326,000 | +27.3% | 90,554 | -5.3% | 0.07% | +22.2% |
| Q2 2019 | $256,000 | -0.4% | 95,598 | +10.0% | 0.05% | -90.1% |
| Q1 2019 | $257,000 | +69.1% | 86,904 | -9.3% | 0.55% | +2003.8% |
| Q4 2018 | $152,000 | -73.9% | 95,817 | -39.5% | 0.03% | -56.7% |
| Q3 2018 | $582,000 | -24.2% | 158,277 | -41.7% | 0.06% | -91.2% |
| Q2 2018 | $768,000 | -21.1% | 271,426 | +3.5% | 0.68% | -19.5% |
| Q1 2018 | $973,000 | +178.8% | 262,284 | +116.3% | 0.84% | +92.7% |
| Q4 2017 | $349,000 | +0.3% | 121,264 | +56.6% | 0.44% | +831.9% |
| Q3 2017 | $348,000 | +7.7% | 77,433 | +10.1% | 0.05% | -2.1% |
| Q2 2017 | $323,000 | +10.6% | 70,350 | +1.3% | 0.05% | -7.7% |
| Q1 2017 | $292,000 | +12.7% | 69,450 | +10.6% | 0.05% | -32.5% |
| Q4 2016 | $259,000 | +18.8% | 62,792 | +133.3% | 0.08% | -26.7% |
| Q3 2016 | $218,000 | +3.8% | 26,915 | 0.0% | 0.10% | -32.7% |
| Q2 2016 | $210,000 | +6.1% | 26,915 | +4.7% | 0.16% | -42.9% |
| Q1 2016 | $198,000 | – | 25,711 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 12,033,220 | $92,896,000 | 11.87% |
| RTW INVESTMENTS, LP | 2,558,859 | $19,754,000 | 7.17% |
| TURNER INVESTMENTS LLC | 859,560 | $6,636,000 | 1.80% |
| DAFNA Capital Management LLC | 236,500 | $1,826,000 | 1.58% |
| Ghost Tree Capital, LLC | 250,000 | $1,930,000 | 1.09% |
| Orbimed Advisors | 11,519,700 | $88,932,000 | 0.94% |
| Rock Springs Capital Management LP | 1,220,000 | $9,418,000 | 0.79% |
| Opus Point Partners Management, LLC | 99,000 | $764,000 | 0.59% |
| Bellevue Group AG | 420,000 | $3,242,000 | 0.59% |
| Cormorant Asset Management, LP | 500,000 | $3,860,000 | 0.58% |